Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Opposing effects of IL-1β/COX-2/PGE2 pathway loop on islets in type 2 diabetes mellitus.

Wang G, Liang R, Liu T, Wang L, Zou J, Liu N, Liu Y, Cai X, Liu Y, Ding X, Zhang B, Wang Z, Wang S, Shen Z.

Endocr J. 2019 May 18. doi: 10.1507/endocrj.EJ19-0015. [Epub ahead of print]

2.

The Effects of Ganglioside-Monosialic Acid in Taxane-induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.

Su Y, Huang J, Wang S, Unger JM, Arias-Fuenzalida J, Shi Y, Li J, Gao Y, Shi W, Wang X, Peng R, Xu F, An X, Xue C, Xia W, Hong R, Zhong Y, Lin Y, Huang H, Zhang A, Zhang L, Cai L, Zhang J.

J Natl Cancer Inst. 2019 May 15. pii: djz086. doi: 10.1093/jnci/djz086. [Epub ahead of print]

PMID:
31093677
3.

Proliferation of human hepatocellular carcinoma cells from surgically resected specimens under conditionally reprogrammed culture.

Wang Z, Bi B, Song H, Liu L, Zheng H, Wang S, Shen Z.

Mol Med Rep. 2019 Jun;19(6):4623-4630. doi: 10.3892/mmr.2019.10160. Epub 2019 Apr 12.

PMID:
31059040
4.

Corrigendum to "Cyclin G2 Suppresses Glomerulosclerosis by Regulating Canonical Wnt Signalling".

Zhao C, Gao J, Li S, Liu Q, Hou X, Liu S, Xing X, Sun M, Wang S, Luo Y.

Biomed Res Int. 2019 Apr 1;2019:4104265. doi: 10.1155/2019/4104265. eCollection 2019.

5.

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Pan Y, Sun Y, Wang H, Ouyang T, Gu K, Feng J, Wang X, Wang S, Liu T, Gao J, Cristofanilli M, Ning Z, Lu X.

Lancet Oncol. 2019 Jun;20(6):806-815. doi: 10.1016/S1470-2045(19)30164-0. Epub 2019 Apr 27.

PMID:
31036468
6.

Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes.

Wang J, Li W, Shi Y, Huang Y, Sun T, Tang L, Lu Q, Lei Q, Liao N, Jin F, Li H, Huang T, Qian J, Pang D, Wang S, Fan P, Wu X, Lin Y, Qin H, Xu B.

Cancer Med. 2019 May;8(5):2074-2084. doi: 10.1002/cam4.2093. Epub 2019 Apr 13.

7.

Panobinostat (LBH589) inhibits Wnt/β-catenin signaling pathway via upregulating APCL expression in breast cancer.

Qin G, Li Y, Xu X, Wang X, Zhang K, Tang Y, Qiu H, Shi D, Zhang C, Long Q, Lee K, Zhai Q, Wang S, Chen M, Deng W.

Cell Signal. 2019 Jul;59:62-75. doi: 10.1016/j.cellsig.2019.03.014. Epub 2019 Mar 14.

PMID:
30880222
8.

Preventing BRCA1/ZBRK1 repressor complex binding to the GOT2 promoter results in accelerated aspartate biosynthesis and promotion of cell proliferation.

Hong R, Zhang W, Xia X, Zhang K, Wang Y, Wu M, Fan J, Li J, Xia W, Xu F, Chen J, Wang S, Zhan Q.

Mol Oncol. 2019 Apr;13(4):959-977. doi: 10.1002/1878-0261.12466. Epub 2019 Mar 1.

9.

CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.

Zhang K, Hong R, Kaping L, Xu F, Xia W, Qin G, Zheng Q, Lu Q, Zhai Q, Shi Y, Yuan Z, Deng W, Chen M, Wang S.

Cancer Lett. 2019 Apr 10;447:130-140. doi: 10.1016/j.canlet.2019.01.005. Epub 2019 Jan 21.

PMID:
30677445
10.

Cyclin G2 Suppresses Glomerulosclerosis by Regulating Canonical Wnt Signalling.

Zhao C, Gao J, Li S, Liu Q, Hou X, Liu S, Xing X, Sun M, Wang S, Luo Y.

Biomed Res Int. 2018 Oct 21;2018:6938482. doi: 10.1155/2018/6938482. eCollection 2018. Erratum in: Biomed Res Int. 2019 Apr 1;2019:4104265.

11.

Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.

Xue C, Wei W, Sun P, Zheng W, Diao X, Xu F, Huang J, An X, Xia W, Hong R, Jiang K, Huang R, Yuan Z, Wang S, Li A, Zou R, Shi Y.

Breast Cancer Res Treat. 2019 Feb;173(3):619-628. doi: 10.1007/s10549-018-4997-2. Epub 2018 Nov 3.

PMID:
30392113
12.

Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis.

Zhang K, Hong R, Xu F, Xia W, Kaping L, Qin G, Zheng Q, Lu Q, Shi YX, Yuan ZY, Wang S.

Cancer Manag Res. 2018 Aug 14;10:2573-2580. doi: 10.2147/CMAR.S173193. eCollection 2018. Review.

13.

Joint Design of Space-Time Transmit and Receive Weights for Colocated MIMO Radar.

Yu Z, Wang S, Liu W, Li C.

Sensors (Basel). 2018 Aug 18;18(8). pii: E2722. doi: 10.3390/s18082722.

14.

Ethylenecarbodiimide-fixed splenocytes carrying whole islet antigens decrease the incidence of diabetes in NOD mice via down-regulation of effector memory T cells and autoantibodies.

Zou J, Gao X, Liu T, Liang R, Liu Y, Wang G, Wang L, Liu N, Sun P, Wang Z, Wang S, Shen Z.

Endocr J. 2018 Sep 27;65(9):943-952. doi: 10.1507/endocrj.EJ18-0158. Epub 2018 Jul 10.

15.

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.

Chi Y, Fang Z, Hong X, Yao Y, Sun P, Wang G, Du F, Sun Y, Wu Q, Qu G, Wang S, Song J, Yu J, Lu Y, Zhu X, Niu X, He Z, Wang J, Yu H, Cai J.

Clin Cancer Res. 2018 Nov 1;24(21):5233-5238. doi: 10.1158/1078-0432.CCR-17-3766. Epub 2018 Jun 12.

PMID:
29895706
16.

Mutations in mevalonate pathway genes in patients with familial or sporadic porokeratosis.

Leng Y, Yan L, Feng H, Chen C, Wang S, Luo Y, Cao L.

J Dermatol. 2018 Jul;45(7):862-866. doi: 10.1111/1346-8138.14343. Epub 2018 May 3.

PMID:
29722423
17.

The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.

An X, Xu F, Luo R, Zheng Q, Lu J, Yang Y, Qin T, Yuan Z, Shi Y, Jiang W, Wang S.

BMC Cancer. 2018 Mar 27;18(1):331. doi: 10.1186/s12885-018-4170-7.

18.

Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial in Type 1 Diabetes Complicated by Severe Hypoglycemia.

Foster ED, Bridges ND, Feurer ID, Eggerman TL, Hunsicker LG, Alejandro R; Clinical Islet Transplantation Consortium.

Diabetes Care. 2018 May;41(5):1001-1008. doi: 10.2337/dc17-1779. Epub 2018 Mar 21.

19.

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group.

Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.

PMID:
29146401
20.

A missense mutation of HOXA13 underlies hand-foot-genital syndrome in a Chinese family.

Cao L, Chen C, Leng Y, Yan L, Wang S, Zhang X, Luo Y.

J Genet. 2017 Sep;96(4):647-652.

Supplemental Content

Loading ...
Support Center